Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks, so it is a positive?
What does this mean for the price going forward? Thanks https://news.bitcoin.com/bitcoin-difficulty-reduction-incoming-miners-brace-for-a-major-shift-on-aug-14
Hi, I am new here. Can someone please explain the "mining difficulty" and the August 14th connection and what you think it all means for the outlook going forward on Bitcoin? Thanks, Ray
Lots of insiders selling lately. Profit taking?
NICE. I was right about CRSP though, but VRTX as I said puzzled me. LOL
Is the 12/8 FDA approval in the price already?
9:10 am ET November 29, 2023 (Benzinga) Print
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here. I think it’s got to come down a little because the stock is losing a lot of money."
Ok so maybe the FDA approval on Dec. 8th is already built into the price of CRSP during it's recent surge? That is kind of what I am thinking that if they do get the approval, that maybe it doesn't go up much more if any at all? But VRTX going down on the UK day of approval seems to me a puzzle?
Ok so maybe the FDA approval on Dec. 8th is already built into the price of CRSP during it's recent surge? That is kind of what I am thinking that if they do get the approval, that maybe it doesn't go up much more if any at all? But VRTX going down on the UK day of approval seems to me a puzzle?
By the way I am 76 years old and my favorite old car was the '57 Chevy.
My mom had a '58 though and my first car was an old '53 Ford. LOL.
Good luck with the book.
My only book can be bought on Kindle: "Making Music Money Memories"
Go VRTX and CRSP.
Why do you think VRTX went down on the day they announced the FDA approval in the UK? And do you think this will go up along with CRSP on DEC. 8th if the FDA approves? These are new to me.
Does anyone think VRTX will get a boost as CRSP would if FDA approves on 12/8?
Wall Street Analysts Believe CRISPR Therapeutics AG (CRSP) Could Rally 33.75%: Here's is How to Trade
9:55 am ET November 20, 2023 (Zacks) Print
CRISPR Therapeutics AG (CRSP) closed the last trading session at $67.89, gaining 75.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $90.80 indicates a 33.8% upside potential.
The mean estimate comprises 20 short-term price targets with a standard deviation of $46.01. While the lowest estimate of $42 indicates a 38.1% decline from the current price level, the most optimistic analyst expects the stock to surge 224.1% to reach $220. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.
But, for CRSP, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Here's What You Should Know About Analysts' Price Targets
According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in CRSP
Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current year, 11 estimates have moved higher over the last 30 days while one has gone lower. As a result, the Zacks Consensus Estimate has increased 26.2%.
Moreover, CRSP currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Therefore, while the consensus price target may not be a reliable indicator of how much CRSP could gain, the direction of price movement it implies does appear to be a good guide.
Yes that would be huge.
Yes son I bought some at $67.96.
A lot in the pipeline: "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States."
smile
Yes and a lot in the pipeline: "TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company’s lead product candidate, envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma. The Company’s other product candidates are YH001, a CTLA-4 antibody that is in Phase I/II development for the treatment of sarcoma; TRC102, a small molecule that is in Phase II clinical development for the treatment of mesothelioma; TJ004309, a CD73 antibody that is in Phase I testing, that is being developed through a collaboration with I-Mab Biopharma, and multiple bispecific antibody programs in preclinical development that are being developed through a collaboration with I-Mab Biopharma. The Company offers partners a solution for the clinical development and commercialization of their products in the United States."
Volume(Heavy Day) 73,872,965 November 21, 2023 3:59pm ET
Yes son I bought some TCON also.
Raiders
OTLK is way oversold on news. Under .25 and target at $1, "Cantor Fitzgerald analyst Kristen Kluska downgrades Outlook Therapeutics (NASDAQ:OTLK) from Overweight to Neutral and lowers the price target from $4.5 to $1."
Price target lowered to $1. "Cantor Fitzgerald analyst Kristen Kluska downgrades Outlook Therapeutics (NASDAQ:OTLK) from Overweight to Neutral and lowers the price target from $4.5 to $1."
Chart saying .80 in a month or so. Just what I see folks.
Don't miss out on the rebound from this over reaction. IMO
Over reaction. "The FDA issues a CRL when it's unable to approve a drug in its current form, and is seeking further confirmatory clinical evidence." They will.
OTLK
NAOV
IMO we are primed for a double in 6 months or so.
CLSK is primed IMO. My opinion of course based on charts and fundamentals, plus the companies digital mining and clean energy focus.
Based in Nevada with 86 employees.
Down 15% after earnings so far premarket.
MACD, A/D, CMF showing this will go up. But who knows? LOL Currently at .82
MSTR is one. Interesting that it is included in 7 stocks to sell in a recession. Hope it doesn't come to that?
https://finance.yahoo.com/news/7-stocks-sell-recession-220039445.html
MIGI - $1.81 - low float
Yes every year older we get, we do get wiser. LOL
Wrong GD. I had HUT way before I knew of tipranks and their price targets. And I was not PUMPING it. I do not even OWN it as of now or when I answered with a post about the CHART comparisons to MARA, RIOT, and HIVE.
I just saw that when it said it has UNDER performed the other bitcoin mining stocks that I wanted to simply SHOW by FACTS that is has not UNDER performed those 3 at least. It has OUT performed them all. (over a year)
I really don't care what you do or anyone else, I just like FACTS.
That is it my friend.
And "if" I do get in it or any other bitcoin mining stock, I only put like 1 or 2 % of my money in it.
So again, I do not look for what agrees with my sentiment, I just like to show facts or articles that MAY help someone else.
I NEVER give MY opinions usually.
But it is ok for you to jump me.
I am 75 years old and I have been jumped many times before.
LOL
OUT perform others. No catalyst. Charts are proof.